Anti-angiogenic agents in metastatic colorectal cancer

Table 1 Bevacizumab in the first-line setting in metastatic colorectal cancer

Ref.	Regimen	PFS (mo)	P value	OS (mo)	P value
Kabbinavar et al[26]; Phase II	1Bolus 5-FU/LV ± bevacizumab	9 vs 5.2 (TTP3)	NA	21.52vs 13.8	NA
Kabbinavar et al[27]; Phase II	1Bolus 5-FU/LV + bevacizumab vs bolus 5-FU/LV + placebo	9.2 vs 5.5	0.0002	16.6 vs 12.9	0.16
Hochster et al[35]; Phase II (TREE-1)	mFOLFOX6/bFOL/CapeOX	8.7/6.9/5.9 (TTP3)	N/A4	19.2/17.9/17.2 18.2 (overall)	N/A4
Hochster et al[35]; Phase II (TREE-2)	mFOLFOX6 + bevacizumab/bFOL + bevacizumab/CapeOX + bevacizumab	9.9/8.3/10.3 (TTP3)		26.1/20.4/24.6 23.7 (overall)
Hurwitz et al[22]; Phase III	IFL + bevacizumab vs IFL + placebo	10.6 vs 6.2	< 0.001	20.3 vs 15.6	< 0.001
Stathopoulos et al[115]; Phase III	IFL ± bevacizumab	NA	NA	22 vs 25	0.1391
Saltz et al[29]; Phase III	FOLFOX/CapeOX + bevacizumab vs FOLFOX/CapeOX + placebo	9.4 vs 8	0.0023	21.3 vs 19.9	0.077

¹Roswell Park regimen: LV 500 mg/m² over 2 h and FU 500 mg/m² as a bolus midway through the LV infusion;

²Data presented is on patients who received chemotherapy plus low-dose bevacizumab;

³Time to progression;

⁴Comparison between outcomes of TREE-1 and TREE-2 is not possible as they were sequential cohorts. 5-FU: 5-Fluorouracil; LV: Leucovorin; PFS: Progression-free survival; OS: Overall survival; mFOLFOX6: Three fluoropyrimidine regimens-infusional 5FU/LV; bFOL: Bolus FU/LV; CapeOX: Capecitabine; FOLFOX: 5-FU/LV/oxaliplatin; NA: Not available; N/A: Not applicable.